Alkermes

Alkermes is a biopharmaceutical company that researches, develops, and commercializes pharmaceutical medicines for central nervous system diseases. Read more

Richard Pops's photo - Chairman & CEO of Alkermes

Chairman & CEO

Richard Pops

CEO Approval Rating

72/100

Founded:

1987

Status:

PublicIndependent CompanyNASDAQALKS

ALKERMES TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Lundbeck is one of Alkermes's top rivals. Lundbeck is a Public company that was founded in 1915 in Valby, Other. Like Alkermes, Lundbeck also works within the Pharmaceuticals industry. Compared to Alkermes, Lundbeck has 3,251 more employees.

Quickbeam is seen as one of Alkermes's biggest rivals. Quickbeam was founded in 2013 in Beaverton, Oregon. Like Alkermes, Quickbeam also competes in the Medical Research & Laboratories sector. Quickbeam generates $1B less revenue than Alkermes.

Polygen is one of Alkermes's top competitors. Polygen was founded in 2015, and its headquarters is in Edgewood, New York. Polygen competes in the industry. Polygen has 2,235 fewer employees than Alkermes.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Conatus a competitor of Alkermes?

Alkermes Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$1B

Alkermes's revenue is the ranked 4th among it's top 10 competitors. The top 10 competitors average 6B. Over the last four quarters, Alkermes's revenue has grown by 1.6%. Specifically, in Q1 2021's revenue was $251.4M; in Q4 2020, it was $280M; in Q3 2020, it was $265M; in Q2 2020, Alkermes's revenue was $247.5M.

Alkermes Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Rodin Therapeutics, Inc.

Nov 2019

Source »
$100M
Rodin is a biotechnology company that discovers, develops and commercializes therapeutics for the treatment of neurologic diseases.

These are all the companies that Alkermes has acquired. Alkermes' latest acquisition was Rodin Therapeutics, Inc. in Nov 2019. Rodin is a biotechnology company that discovers, develops and commercializes therapeutics for the treatment of neurologic diseases.

Alkermes Funding History

No recent funding data found related to Alkermes

Alkermes Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

Civitas develops pulmonary delivery therapies.
$55M
Aug 21, 2014
Series C
Sep 01, 2014
Civitas develops pulmonary delivery therapies.
$38M
Sep 11, 2013
Series B
Sep 01, 2014
Civitas develops pulmonary delivery therapies.
$14.3M
Jun 18, 2013
Unattributed
Sep 01, 2014

These are all the companies that Alkermes has invested in. Alkermes' latest investment was Rodin Therapeutics, Inc. in Nov 2019. Rodin is a biotechnology company that discovers, develops and commercializes therapeutics for the treatment of neurologic diseases.

Alkermes News

June 4, 2021Markets Insider

Alkermes to Take Part in the Goldman Sachs Annual Global Healthcare Conference

DUBLIN, June 3, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will... See more »
June 1, 2021Endpoints News

Alkermes wins FDA nod for combo med with antipsychotic olanzapine - this time without the weight gain red flags

Alkermes has had a rough go in the past few years, making the decision to slice away a healthy portio... See more »
May 28, 2021Markets Insider

Alkermes to Host Webcast With Expert Oncologist Panel to Discuss Data on Nemvaleukin Alfa Presented at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

DUBLIN, May 28, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will host a ... See more »
May 22, 2021CNBC

Biopharma company faces pressure to trim costs and maximize value for shareholders

Alkermes, a biopharmaceutical company, benefits from profitable drugs and royalties, but a "bloated c... See more »
May 13, 2021BioSpace

Alkermes Announces 2021 Alkermes Inspiration Grants Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental Illness or Cancer

Alkermes plc (Nasdaq: ALKS) today announced that the company will begin accepting applications for it... See more »
May 6, 2021PharmaLeaders

Alkermes Launches New Website Offering Education About Alcohol Dependence

Myrelationshipwithalcohol.com offers educational information about alcohol dependence, an interactive... See more »
May 6, 2021FiercePharma

Alkermes debuts alcohol dependency campaign as pandemic fuels increased drinking

Alkermes debuts alcohol dependency campaign as pandemic fuels increased drinking sharon.coey Thu, 05/... See more »

Alkermes Press Releases

August 17, 2020PR Newswire

American Journal of Psychiatry Publishes Data From Alkermes' Phase 3 ENLIGHTEN-2 Weight Study of ALKS 3831 in Patients With Schizophrenia

DUBLIN, Aug. 17, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the publication of ... See more »
June 22, 2020PR Newswire

New Preclinical Data on ALKS 4230 in Combination With Lucitanib to be Presented at 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II

DUBLIN and BOULDER, Colo., June 22, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) and Clovis Oncol... See more »
June 19, 2020CSRwire

Our Responsibility to Combat Discrimination and Racism

Originally published on LinkedInLast week, more than 1,000 Alkermes employees came together virtually... See more »
May 7, 2020CSRwire

Collaborative and Risk-focused Engagement (CaRE ) at Alkermes

Alkermes 2019 Corpororate Responsibility ReportIn 2018, we significantly enhanced CaRE , our propriet... See more »
February 4, 2020Business Wire

Lieff Cabraser Files California Wrongful Death Case Against Alkermes Over Vivitrol Opioid Dependence Drug

LOS ANGELES--(BUSINESS WIRE)-- #Alkermes--Lieff Cabraser files California wrongful death case against... See more »
December 11, 2019PR Newswire

FDA issues warning letter for not including the most serious risks in advertisement for medication-assisted treatment drug

SILVER SPRING, Md., Dec. 11, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration today posted ... See more »

Alkermes Videos

Social Media

Alkermes Headquarters

1 Burlington Road Connaught House

Dublin, County Westmeath

353-1-772-8000

Driving Directions »

Trending Companies

Alkermes Summary

ABOUT

Overview

Alkermes is a biopharmaceutical company that researches, develops, and commercializes pharmaceutical medicines for central nervous system diseases. Alkermes was founded in 1987. Alkermes' headquarters is located in Dublin, County Westmeath, IE . Alker...

CEO

Alkermes's Chairman & CEO, Richard Pops, currently has an approval rating of 72%. Alkermes's primary competitors are Lundbeck, Quickbeam & Polygen.

Frequently Asked Questions about Alkermes

  1. When was Alkermes founded?

    Alkermes was founded in 1987
  2. Who is Alkermes's CEO?

    Alkermes's CEO is Richard Pops
  3. How much revenue does Alkermes generate?

    Alkermes generates $1B in revenue
  4. How much funding does Alkermes have?

    Alkermes has historically raised $0 in funding
  5. Where is Alkermes's headquarters?

    Alkermes's headquarters is in Dublin County Westmeath, IE
  1. How many employees does Alkermes have?

    Alkermes has 2,300 employees
  2. What sector does Alkermes operate in?

    Alkermes is in Pharmaceuticals, Biotechnology, Medical Research & Laboratories
  3. Who are Alkermes's competitors?

    Alkermes's top competitors are Lundbeck, Quickbeam, Polygen
  4. Who has Alkermes invested in?

    Alkermes's has invested in companies such as Civitas Therapeutics, Inc., Civitas Therapeutics, Inc., Civitas Therapeutics, Inc.